Back to top
more

Catalent (CTLT)

(Real Time Quote from BATS)

$60.00 USD

60.00
715,782

+0.05 (0.08%)

Updated Nov 7, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks News

Why Catalent (CTLT) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Catalent (CTLT) Q1 Earnings Top Estimates, FY22 View Up

Catalent's (CTLT) robust performance across most of its segments drives its first-quarter fiscal 2022 top line.

Catalent (CTLT) Q1 Earnings and Revenues Surpass Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 7.58% and 1.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Earnings Expected to Grow: Should You Buy?

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalent (CTLT) to Report Q1 Earnings: What's in Store?

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Catalent (CTLT) Expands Presence in Japan Via New Facility

Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific Corp, Catalent, Baxter International and Hill-Rom Holdings

Debanjana Dey headshot

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

Why Is Catalent (CTLT) Up 2.1% Since Last Earnings Report?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Catalent (CTLT) Stock For Now

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Moderna (MRNA) Inks Vaccine Manufacturing Deal With Resilience

Moderna (MRNA) is expanding its manufacturing and fill-finish capacities through collaborations deals with multiple companies to support the supply of its COVID-19 vaccine.

Catalent's (CTLT) Q4 Earnings Top Estimates, Margins Rise

Catalent's (CTLT) robust performance across the majority of its segments drives its fourth-quarter fiscal 2021 top line.

Catalent (CTLT) Q4 Earnings and Revenues Surpass Estimates

Catalent (CTLT) delivered earnings and revenue surprises of 11.54% and 5.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) to Report Q4 Earnings: What's in Store?

Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q4 results.

Catalent (CTLT) Earnings Expected to Grow: Should You Buy?

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals, and integrated development and product supply chain solutions.

Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate

The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.

Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia

Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.

Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates

Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.

Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK

Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.